Chemomab Therapeutics Ltd.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2019 | $-3.1M | $-3.2M | $75.0K | $380.0K |
| Jun 2019 | $-3.9M | $-3.9M | $16.0K | $368.0K |
| Sep 2019 | $-3.5M | $-3.8M | $255.0K | $321.0K |
| Dec 2019 | $-5.9M | $-5.7M | $-251.0K | $89.0K |
| Mar 2020 | $-1.9M | $-1.9M | $10.0K | $46.0K |
| Jun 2020 | $-873.0K | $-880.0K | $7.0K | $28.0K |
| Sep 2020 | $-901.0K | $-921.0K | $20.0K | $23.0K |
| Dec 2020 | $-1.6M | $-1.6M | $1.0K | $33.0K |
| Mar 2021 | $-1.3M | $-1.3M | $3.0K | $43.0K |
| Jun 2021 | $-5.6M | $-5.7M | $102.0K | $527.0K |
| Sep 2021 | $-2.6M | $-2.6M | $0 | $441.0K |
| Dec 2021 | $-2.9M | $-3.0M | $134.0K | $1.0M |
| Mar 2022 | $-3.7M | $-3.7M | $14.0K | $874.0K |
| Jun 2022 | $-5.7M | $-5.7M | $11.0K | $761.0K |
| Sep 2022 | $-5.3M | $-5.3M | $42.0K | $836.0K |
| Dec 2022 | $-5.7M | $-5.7M | $1.0K | $740.0K |
| Mar 2023 | $-7.2M | $-7.2M | $1.0K | $484.0K |